The effect of bezafibrate on hyperlipidaemia in experimental nephrotic syndrome in rats.
The effects of bezafibrate on hyperlipidaemia in experimental nephrotic syndrome in rats has been investigated. The treated group received bezafibrate 10 mg kg-1 p.o. daily. No significant differences in total serum cholesterol occurred, but a significant reduction in serum triglyceride (P less than 0.005) and elevation in HDL cholesterol (P less than 0.005) occurred. These findings may have implications for therapeutic intervention in severe hyperlipidaemia of the nephrotic syndrome in man.
Williams
A J
AJ
Baker
F E
FE
Walls
J
J
D000818:Animals; D001629:Bezafibrate / Q000494:pharmacology*; D001798:Blood Proteins / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000209:etiology; D009404:Nephrotic Syndrome / Q000150:complications*; D011485:Protein Binding; D051381:Rats; D011919:Rats, Inbred Strains; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
D001798:Blood Proteins; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D014280:Triglycerides; D002784:Cholesterol; D001629:Bezafibrate